Literature DB >> 25344970

[Diagnostic importance of pentraxins at the early phase of acute pancreatitis].

Piotr Meryk, Paulina Dumnicka, Beata Kuśnierz-Cabala, Marek Kuźniewski, Maria Kapusta, Anna Gurda-Duda, Marek Goebels, Dorota Pawlica-Gosiewska, Jan Kulig.   

Abstract

Pentraxins are among the main acute phase reactants. There are two types of pentraxins, i.e., long, including pentraxin 3 (PTX3) and short, including C-reactive protein (CRP) and serum amyloid A (SAA). The aim of the study was to assess the increase in serum concentrations of pentraxins (ex- pressed as the multiplicity of the upper reference limits) and their usefulness in prognosing severe course of acute pancreatitis (AP) in the early phase of the disease. Forty patients admitted to Ist Department of Surgery, Jagiel-Ionian University Medical College with the diagnosis of AP were recruited for the study. In the early phase of AP, the concentrations of PTX3 achieved maximum earlier than CRP or SAA, enabling to differentiate between mild and moderate or severe AP in the first day of the disease. Also, during the first 24 hours from beginning of AP, SAA achieved its best prognostic value. Of all pentraxins studied, SAA was characterized by the most significant increase as compared to the upper reference limit. The prognostic utility of CRP increased later, after 48 hours of AP.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25344970

Source DB:  PubMed          Journal:  Przegl Lek        ISSN: 0033-2240


  2 in total

1.  Inflammatory mediators in the diagnosis and treatment of acute pancreatitis: pentraxin-3, procalcitonin and myeloperoxidase.

Authors:  Osman Simsek; Ahmet Kocael; Pınar Kocael; Anıl Orhan; Mahir Cengiz; Huriye Balcı; Kenan Ulualp; Hafize Uzun
Journal:  Arch Med Sci       Date:  2018-02-21       Impact factor: 3.318

2.  Correlation between PCT, 25(OH)D, PTX-3, AMS levels and the severity of diabetic ketoacidosis complicated by pancreatitis.

Authors:  Songtao Lu; Dongmei Wei; Chao Yin; Juwen Xiong; Lishuang Zhu; Shaoru Yan; Rui Meng
Journal:  BMC Endocr Disord       Date:  2021-06-29       Impact factor: 2.763

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.